Novavax reported 'positive data' on its experimental coronavirus vaccine on Wednesday.
Its phase one trial in more than 100 Australian adults showed that the vaccine triggered the production of coronavirus antibodies - infection-fighting immune cells - in everyone that got the shot after their second dose.
No one involved in the early safety testing reported any serious side effects, and most 'adverse events' were deemed unrelated to the vaccine, according to a report published in the New England Journal of Medicine (NEJM).
On the the heels of the results, Novavax announced that it it has launched the second half of the trial, in adults between ages 60 and 84 in the US and Australia.
Shares for Novavax rose four percent after the bell, and the results' publication.
It comes after the Centers for Disease Control and Prevention (CDC) sent instructions to state health departments to prepare for COVID-19 vaccines to be shipped by the end of October - days before the November 3 Presidential election.
Novavax's vaccine uses synthesized pieces of the surface protein that the coronavirus uses to invade human cells and spurs antibody production. Pictured: Three potential coronavirus vaccines are kept in a tray at Novavax labs in Gaithersburg, Maryland (file)
For the first half of its phase 1/2 trial of its coronavirus vaccine, called NVX-CoV2373, Novavax dosed 108 volunteers between ages 18 and 59 with its vaccine.
Eighty-three of those were given an adjuvanted form - a shot containing an immune response booster - while 25 got the vaccine sans adjuvant.
All participants were vaccinated in two doses.
All of the participants who got the shot with the extra immune response-booster developed antibodies in response to the 'spike' protein on the surface of the coronavirus.
Some of them also developed 'neutralizing' antibodies - those that may be most capable of blocking the virus from invading cells.
After a second dose of either form of the shot, everyone developed antibodies.
As has been the case with all vaccines that have reached clinical